Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc R&D Day Transcript

Apr 07, 2021 / 05:00PM GMT
Release Date Price: $26.53 (-2.28%)
Will Gramig

Good afternoon. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' 2021 R&D Day. As a reminder, we will be making some forward-looking statements today. We would encourage you to review Cara's most recent SEC filings for a more complete description of our risk factors.

Cara management is delighted to be joined on the webinar today by 2 highly accomplished key opinion leaders, Dr. Brian Kim and Dr. Mark Lebwohl. Dr. Brian Kim is an Associate Professor of Medicine and the Co-Director of the Center for the Study of Itch and Sensory Disorders at Washington University School of Medicine in St. Louis. Dr. Mark Lebwohl is a professor of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York. Participating from Cara today will be Dr. Derek Chalmers, Cara's President and Chief Executive Officer; Dr. Joana Goncalves, Cara's Chief Medical Officer; Mr. Eric Vandal, Cara's Senior Vice President of Commercial Operations; and Mr. Tom Reilly, Cara's Chief Financial Officer.

Today's event is expected to run

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot